Recombinant human monoclonal antibody to Cannabinoid Receptor I.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivité
Human, Cynomolgus Macaque
Hôte
Human
Clonalité
Monoclonal
Isotype
IgG4
Chaînes légères
kappa
Conjuguer
Unconjugated
Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Masse moléculaire
This antibody has a predicted MW of 145 kDa.
Pureté
> 95% (by SDS-PAGE and SEC-HPLC).
Forme du produit
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Stockage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
SDS-PAGE analysis of Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) under reducing (R) conditions confirms that the purity of this antibody is greater than 95%.
SEC-HPLC analysis of Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) confirms that the purity of this antibody is 99.42%.
Immobilized recombinant human CB1 VLP protein at 5 µg/ml (30 uL/well) is bound by Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607). EC50 was approximately 0.04092 µg/ml.
Human CB1 / CNR1 EGFP HEK293 Cell Line were stained with Nimacimab Biosimilar - Anti-Cannabinoid Receptor I Antibody - Low endotoxin, Azide free (A323607) and negative control protein respectively, washed and then followed by APC and analyzed with FACS, EC50 = 0.028 µg/ml.
Produits alternatifs à Anti-Cannabinoid Receptor I Anticorps (A323607)